Sanara MedTech Inc (NAS:SMTI)

Q3 2024 Sanara Medtech Inc Earnings Call Transcript

Nov 13, 2024 / 02:00 PM GMT

Release Date Price: $37.22 (+7.57%)

Transcript 8-K10-Q

Key Points

Positve

Sanara MedTech Inc (SMTI) reported a 35% year-over-year increase in net revenue for Q3 2024, marking its 12th consecutive record revenue quarter.
The company achieved an improved adjusted EBITDA of $800,000 in Q3 2024, up from $300,000 in the same period of 2023.
Sanara MedTech Inc (SMTI) expanded its product reach, with sales in over 1,200 hospitals across 34 states and the District of Columbia.
The company is actively investing in its THP technology platform, with a commercial launch expected in mid-2025.
Sanara MedTech Inc (SMTI) has established strategic partnerships, including a $5 million investment in Chemo Mouthpiece LLC, aligning with its wound and skin care strategy.

Negative

The surgical segment reported a net loss of $200,000 in Q3 2024 and a year-to-date net loss of $2.9 million.
SG&A expenses increased significantly to $19 million in Q3 2024 from $13.9 million in the same period of 2023.
The company reported a net loss of $2.9 million for Q3 2024, compared to a net loss of $1.1 million in Q3 2023.
Interest expenses rose to $900,000 in Q3 2024, up from $200,000 in Q3 2023, primarily due to a term loan.
The Tissue Health Plus segment generated a negative segment EBITDA of $1.7 million during Q3 2024.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SMTI.OQ - Sanara Medtech Inc
Q3 2024 Sanara Medtech Inc Earnings Call
Nov 13, 2024 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Sonera MedTech third quarter, 2024 earnings conference call.

The company issued its earnings release yesterday and will post today's supplemental deck on the investor relations page on the company's website with us today are Ron Nixon, executive Chairman and CEO Mike mcneil, Chief Financial Officer Sethia, President, Commercial and SAM Mapa who leads tissue health plus.

Please note that certain statements in this conference call in our press release and in our supplemental deck include forward-looking statements within the meaning of the private securities Litigation Reform Act of 1,995.

For more information about the risks and uncertainties involving forward-looking statements

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.